Switch theme
Sign up to access all valuation multiples
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The firm's core products are dental implants, and it holds over one third of the CHF 6 billion global market. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
1954
11.8K+
LTM Revenue $3.1B
LTM EBITDA $965M
$20.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Straumann Group has a last 12-month revenue (LTM) of $3.1B and a last 12-month EBITDA of $965M.
In the most recent fiscal year, Straumann Group achieved revenue of $3.0B and an EBITDA of $872M.
Straumann Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Straumann Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.1B | XXX | $3.0B | XXX | XXX | XXX |
| Gross Profit | $2.2B | XXX | $2.1B | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | $965M | XXX | $872M | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 29% | XXX | XXX | XXX |
| EBIT | $804M | XXX | $722M | XXX | XXX | XXX |
| EBIT Margin | 26% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $590M | XXX | $466M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 16% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Straumann Group's stock price is CHF 106 (or $127).
Straumann Group has current market cap of CHF 16.8B (or $20.2B), and EV of CHF 16.9B (or $20.2B).
See Straumann Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $20.2B | $20.2B | XXX | XXX | XXX | XXX | $3.94 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Straumann Group has market cap of $20.2B and EV of $20.2B.
Straumann Group's trades at 6.7x EV/Revenue multiple, and 23.2x EV/EBITDA.
Equity research analysts estimate Straumann Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Straumann Group has a P/E ratio of 34.3x.
See valuation multiples for Straumann Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $20.2B | XXX | $20.2B | XXX | XXX | XXX |
| EV (current) | $20.2B | XXX | $20.2B | XXX | XXX | XXX |
| EV/Revenue | 6.5x | XXX | 6.7x | XXX | XXX | XXX |
| EV/EBITDA | 21.0x | XXX | 23.2x | XXX | XXX | XXX |
| EV/EBIT | 25.2x | XXX | 28.1x | XXX | XXX | XXX |
| EV/Gross Profit | 9.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 34.3x | XXX | 43.3x | XXX | XXX | XXX |
| EV/FCF | 41.8x | XXX | 53.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialStraumann Group's last 12 month revenue growth is 9%
Straumann Group's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Straumann Group's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Straumann Group's rule of X is 53% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Straumann Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 31% | XXX | XXX | XXX |
| Rule of 40 | 29% | XXX | 38% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 53% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Straumann Group acquired XXX companies to date.
Last acquisition by Straumann Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Straumann Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Straumann Group founded? | Straumann Group was founded in 1954. |
| Where is Straumann Group headquartered? | Straumann Group is headquartered in Switzerland. |
| How many employees does Straumann Group have? | As of today, Straumann Group has 11.8K+ employees. |
| Is Straumann Group publicy listed? | Yes, Straumann Group is a public company listed on SWX. |
| What is the stock symbol of Straumann Group? | Straumann Group trades under STMN ticker. |
| When did Straumann Group go public? | Straumann Group went public in 2001. |
| Who are competitors of Straumann Group? | Similar companies to Straumann Group include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Straumann Group? | Straumann Group's current market cap is $20.2B |
| What is the current revenue of Straumann Group? | Straumann Group's last 12 months revenue is $3.1B. |
| What is the current revenue growth of Straumann Group? | Straumann Group revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Straumann Group? | Current revenue multiple of Straumann Group is 6.5x. |
| Is Straumann Group profitable? | Yes, Straumann Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Straumann Group? | Straumann Group's last 12 months EBITDA is $965M. |
| What is Straumann Group's EBITDA margin? | Straumann Group's last 12 months EBITDA margin is 31%. |
| What is the current EV/EBITDA multiple of Straumann Group? | Current EBITDA multiple of Straumann Group is 21.0x. |
| What is the current FCF of Straumann Group? | Straumann Group's last 12 months FCF is $484M. |
| What is Straumann Group's FCF margin? | Straumann Group's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of Straumann Group? | Current FCF multiple of Straumann Group is 41.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
